FTC et al. v. Vyera Pharmaceuticals, No. 1:20-cv-00706 (S.D.N.Y. Apr. 19, 2020)
January 4, 2021
The FTC, New York and six other states filed suit against Vyera Pharmaceuticals, its parent company, Phoenixus, and its former officers, Kevin Mulleady and Martin Shkreli in 2020, alleging anticompetitive conduct in connection with Daraprim, the only FDA approved drug for the treatment of the life-threatening parasitic disease toxoplasmosis. The suit alleged that Vyera purchased…
